From Single-Cell to Spatial Intelligence: The Next Era of Precision Medicine

Abstract:

Spatial omics technologies are transforming precision medicine by revealing cellular organisation and molecular interactions within intact tissues. Combined with single-cell genomics and AI-driven analytics, these approaches are advancing biomarker discovery, therapeutic development, and translational research, enabling a deeper understanding of disease biology and more targeted clinical strategies.

1. Spatial omics is often described as the missing contextual layer in molecular biology. How is spatial intelligence redefining our understanding of disease mechanisms compared to traditional bulk sequencing and even single-cell analysis?

Spatial omics refers to a group of high-resolution in situ technologies that measure gene and/or protein expression while preserving the spatial location of cells within intact tissues, enabling researchers to study molecular activity in its native biological context. Spatial omics has rapidly become one of the most exciting advances in biomedical research over the past few years including spatial transcriptomics and spatial proteomics technologies which have been named Nature Methods Method of the Year in 2020 and 2024, respectively. With these powerful technologies, researchers can now study complex tissue ecosystems and immune microenvironments with an unprecedented level of detail. This is fundamentally changing how we understand cellular interactions, disease biology, and tissue architecture across both research and translational applications. 

Spatial omics is transforming molecular medicine by preserving the architectural and cellular context that is lost in bulk sequencing and partially fragmented in dissociative single-cell analysis. Traditional bulk sequencing assays average signals across diverse cell populations, which can hide significant but rare cellular interactions. While single-cell genomics significantly improved resolution, the tissue dissociation process can disrupt the spatial relationships, stromal structure, and immune localisation patterns that are often critical to understanding disease progression. 

Spatial omics provides a significant advantage over traditional bulk sequencing and single-cell analysis by preserving the spatial organisation of cells within intact tissues. This enables researchers to study cell-cell interactions, tissue architecture, and microenvironmental influences that are lost when tissues are dissociated. Spatial omics is also particularly valuable for hard tissues, such as bone, calcified tissues, or arteries that are difficult or impossible to dissociate, making conventional single-cell or Total RNA sequencing challenging or infeasible. By retaining spatial context, researchers can gain a more comprehensive understanding of disease mechanisms and identify biologically relevant cellular niches that drive disease progression and treatment response.

Spatial omics provides a systems-level view of tissues by linking molecular data with cellular location. In oncology, neuroscience, and inflammatory diseases, spatial organisation reveals critical cellular interactions and signaling patterns that cannot be captured by transcript data alone. This contextual insight is becoming increasingly important for biomarker discovery, patient stratification, and therapeutic target validation.

2. The convergence of single-cell genomics, spatial transcriptomics, and AI is accelerating rapidly. Which technological inflection points do you believe will have the greatest clinical impact over the next five years, and why? And what role will AI and machine learning play in extracting clinically meaningful insights from these massive biological data systems?

Innovation is key! The next major breakthrough will come from combining high-resolution spatial transcriptomics with multimodal artificial intelligence (AI) and machine learning (ML). While single-cell sequencing helped classify cells, the focus is now on using these data to better understand tissue biology and disease in their natural environment. AI and ML will be essential for transforming spatial biology into a clinically scalable decision-support tool. By integrating spatial RNA data, pathology imaging, and predictive models, these technologies can uncover clinically relevant spatial signatures, improve patient stratification, and support the development of diagnostics that guide more personalized treatment decisions.
Another key development will be scalable FFPE tissue-compatible workflows, enabling researchers to unlock valuable insights from large clinical cohorts and archived tissue samples. Clinically, the ability to identify predictive spatial biomarkers for treatment response, fibrosis progression, neurodegeneration, and inflammatory activity has the potential to transform precision medicine. 

3. One of the biggest challenges in precision medicine is translating molecular insights into actionable therapies. How are spatial omics platforms improving biomarker validation and patient stratification in real-world clinical settings?

Spatial omics platforms are improving translational relevance by allowing researchers and clinicians to validate biomarkers directly within the tissue microenvironment where disease biology occurs. Unlike bulk biomarkers, spatial biomarkers incorporate both molecular identity and positional context, which is often critical for therapeutic response. This means clinicians could personalize treatments more accurately based on someone unique genetic information.

In oncology, understanding where immune cells are located within the tumor microenvironment is often as important as knowing they are present. Their spatial organisation can strongly influence treatment response, making spatial technologies highly valuable for patient stratification. These approaches are also improving identification of responder and non-responder populations in immunotherapy and are increasingly being integrated into companion diagnostics and translational drug development.

4. Cancer research has been an early adopter of spatial biology approaches. How are these technologies reshaping our understanding of the tumor microenvironment, immune interactions, metastasis, and therapeutic resistance? How close are we to using spatially resolved data to accurately predict disease progression or therapeutic response?

Spatial biology has transformed our understanding of tumors by revealing them as complex ecosystems rather than uniform masses of cancer cells. Spatial transcriptomics and proteomics now enable researchers to map immune exclusion zones, suppressive macrophage niches, tertiary lymphoid structures, and clonal heterogeneity directly within intact tissues. These insights are helping explain variability in immunotherapy response and mechanisms of treatment resistance.

The field is rapidly advancing toward predictive spatial biology, with growing evidence linking spatial biomarkers to therapeutic response, particularly in oncology and immunology. However, widespread clinical adoption will require standardized workflows, harmonised analytical pipelines, and large-scale regulatory validation.

Spatial approaches are also improving our understanding of metastatic evolution by showing how tumor cells adapt to different tissue environments. For pharmaceutical companies, this creates new opportunities to develop therapies targeting not only tumor cells themselves, but also the spatially organised cellular interactions that drive disease progression and resistance.

5. The spatial omics field has experienced rapid technological innovation, resulting in a diverse ecosystem of platforms with distinct capabilities and limitations. How should researchers approach technology selection to ensure the best fit for their biological or clinical questions? Are all spatial omics technologies equally informative, or do differences in performance, scalability, and translational potential make some approaches better suited for specific applications?

It is essential that technology selection in spatial omics starts with the biological or clinical question—not with the technology itself. One of the biggest misconceptions in the field is the idea that there is a universally “best” platform. In reality, each spatial omics technology represents a different trade-off between resolution, throughput, molecular depth, tissue coverage, scalability, cost, and translational readiness.

Not all spatial omics technologies are equally informative for every application. The ideal platform depends on whether the goal is discovery research, tissue architecture analysis, biomarker validation, or clinical translation. Some technologies provide exceptional single-cell or subcellular resolution, while others prioritise transcriptome breadth, throughput, or scalability. In translational and clinical settings, factors such as reproducibility, FFPE compatibility, automation, workflow robustness, and data interpretability become essential.

Ultimately, successful adoption of spatial omics depends on aligning technological capabilities with the specific scientific, clinical, and operational objectives of the study. The field is evolving rapidly, and the strongest outcomes typically come from technology decisions driven by biological relevance and implementation strategy—not by hype or resolution alone.

6. Multi-omics integration remains a major scientific and computational challenge. What are the key barriers to harmonising genomic, transcriptomic, proteomic, and spatial data into a unified precision framework?

The main challenge in multi-omics integration is that each modality captures different aspects of biology and comes with its own technical biases, dynamic ranges, and spatial resolutions. Combining genomic, transcriptomic, proteomic, and spatial data into a unified framework requires advanced computational tools, scalable infrastructure, and robust statistical methods. Data standardization across platforms, laboratories, and clinical sites remains a significant hurdle, highlighting the need for collaborative efforts and high-quality reference datasets.

Equally important is the ability to translate complex datasets into meaningful, actionable insights. Clinicians, pharmaceutical and industry leaders need clear results that support decision-making. Ultimately, the success of precision medicine will depend on analytical platforms that can transform multi-omics data into clinically relevant knowledge.

7. Clinical adoption depends heavily on reproducibility, scalability, and cost-effectiveness. What advancements are still needed before spatial omics becomes a routine component of hospital diagnostics and clinical workflows?

Several advances are needed before spatial omics becomes a routine clinical diagnostic tool. Workflows must be standardized across sample preparation, imaging, sequencing, and data analysis to ensure reproducibility between laboratories. Scalability, cost reduction, and workflow simplification are also essential, as current approaches often require specialized equipment, computational resources, and expertise. In addition, clinically validated biomarkers supported by prospective studies are needed to demonstrate utility in patient management. Spatial omics will likely be adopted gradually, beginning with high-impact applications in oncology and immunology where clinical benefits are most evident.

8. Regulatory and standardization issues are becoming increasingly important in next-generation diagnostics. How should the industry address validation standards, data interoperability, and regulatory approval pathways for spatial biology technologies?

To accelerate clinical adoption, the field needs greater collaboration among technology developers, pharmaceutical companies, clinical laboratories, regulators, and academic researchers. Standardized validation frameworks are essential to ensure results are reproducible and comparable across platforms and institutions. Common reference tissues and benchmarking datasets will help evaluate technologies objectively.

Data integration is just as important, since spatial biology data needs to work smoothly alongside pathology, genomic, and clinical information systems. From a regulatory standpoint, adoption will likely begin with applications that demonstrate clear clinical value, particularly companion diagnostics that help predict and guide therapeutic response.

9. Drug discovery pipelines are evolving toward increasingly targeted and personalized approaches. How are pharmaceutical and biotech companies leveraging spatial intelligence to improve target identification and reduce late-stage clinical failures?

Pharmaceutical and biotech companies are increasingly using spatial biology to understand not only which molecular targets are present, but also how they interact within the tissue environment. This context is important because treatment response is often driven by cellular interactions rather than individual molecules alone.

Spatial biology helps identify targets linked to immune suppression, inflammation, and treatment resistance, improving confidence in early drug discovery. It is also being used to develop predictive biomarkers and better stratify clinical trial participants. By identifying spatial signatures associated with treatment response, companies can design more targeted trials and improve the likelihood of clinical success.

10. There is growing interest in applying spatial omics beyond oncology into neurology, immunology, and rare diseases. Which therapeutic areas do you believe are poised for the next major breakthrough, and what makes them particularly suitable for spatial analysis?

Neurology and immunology are especially promising areas for spatial omics because both rely on complex cellular interactions within highly organised tissues. In the brain, spatial organisation influences neuronal function, neuroinflammation, and disease progression, making spatial omics particularly valuable for studying disorders such as Huntington's disease, Alzheimer’s disease, and Parkinson’s disease.

In immunology, spatial profiling helps reveal how immune cells interact with surrounding tissues in diseases such as inflammatory bowel disease, lupus, rheumatoid arthritis, and giant cell arteritis. Rare diseases may also benefit, as spatial analysis can uncover localised disease mechanisms that are often missed by conventional approaches.

11. Precision medicine and healthcare ethics remain central to data governance considerations. How should healthcare systems balance innovation with concerns surrounding patient privacy, data ownership, and equitable access to advanced molecular diagnostics?

As spatial omics becomes more widely adopted, healthcare systems will need clear policies that support innovation while protecting patient privacy and data security. Because these datasets are often linked to clinical, imaging, and genomic information, strong safeguards are essential. This includes secure data management, transparent consent processes, and clear communication about how patient data may be used in research, AI development, and commercial collaborations.

Ensuring equitable access is equally important. If advanced molecular diagnostics remain limited to major research centers, healthcare disparities could widen. Reducing costs and improving accessibility will be critical for broad clinical adoption.

12. As pharmaceutical companies increasingly invest in AI-enabled biomarker discovery, how do you see the relationship evolving between computational scientists, translational biologists, and clinical decision-makers?

The future of precision medicine will rely on closer collaboration between computational scientists, biologists, clinicians, and drug development teams. Spatial biology and AI bring together expertise from multiple disciplines, including molecular biology, pathology, imaging, data science, and clinical medicine.

As datasets become increasingly complex, no single field can work in isolation. Computational findings must be continuously validated against biological and clinical evidence to ensure they are meaningful and actionable. Organisations that successfully connect scientific, clinical, and computational expertise will be best positioned to accelerate biomarker discovery, improve patient care, and advance the development of new therapies.

13. Looking ahead, what do you believe will define the next generation of spatial biology platforms, and how might these technologies ultimately reshape the future of precision medicine?

The next generation of spatial biology platforms will be defined by higher plexity, multimodal integration, automation, scalability, and clinically deployable analytical ecosystems. Future technologies will integrate RNA, proteins, morphology, epigenetics, cellular interactions, and additional layers such as the genome, microbiome, virome, glycome, and biophysical tissue properties within unified spatial frameworks. These advances aim to provide a more comprehensive understanding of tissue function and disease biology. 

Another major trend is the convergence of spatial biology with AI-driven predictive modeling, shifting the field from exploratory research toward clinically actionable insights. Ultimately, these technologies could reshape precision medicine by enabling clinicians to study disease within functional tissue ecosystems, improving patient stratification, accelerating therapeutic development, and supporting more personalized treatment strategies across multiple disease areas.

14: As we look to the future, what is the key takeaway for the industry?

The greatest opportunity lies in our ability to move beyond isolated biomarkers and develop a truly systems-level understanding of human disease. By integrating spatial biology with multi-omics data and AI-driven analytics, we can begin to understand how cells, tissues, and molecular networks interact in their native environment. This has the potential to transform precision medicine by enabling more accurate patient stratification, earlier disease detection, better therapeutic targeting, and more personalized treatment strategies.

However, realising this vision will require overcoming several important challenges. Standardization, scalability, regulatory validation, data integration, and equitable access remain critical barriers to widespread adoption. Equally important is the need to ensure that increasingly complex analytical systems remain interpretable and clinically actionable. As these technologies generate larger and more complex datasets, data storage and infrastructure capacity are also becoming major challenges that the field will need to address.

AI's greatest strength may also be one of its greatest limitations. Despite its transformative potential, AI still operates largely as a "black box." We can often observe what decision is made, but not fully understand why it was made. This lack of transparency remains a major barrier to trust, adoption, and regulatory acceptance in clinical decision-making.

Ultimately, the future of precision medicine will depend not only on generating more data, but on our ability to translate complex biological information into trustworthy, actionable insights that improve patient outcomes. Organisations that successfully combine scientific innovation, clinical validation, and responsible AI will be best positioned to shape the next era of healthcare.